| Literature DB >> 30488778 |
Sarp Bamyaci1,2, Roland Nordfelth1,2, Åke Forsberg1,2.
Abstract
Type III secretion systems (T3SSs) are tightly regulated key virulence mechanisms shared by many Gram-negative pathogens. YopN, one of the substrates, is also crucial in regulation of expression, secretion and activation of the T3SS of pathogenic Yersinia species. Interestingly, YopN itself is also targeted into host cells but so far no activity or direct role for YopN inside host cells has been described. Recently, we were able show that the central region of YopN is required for efficient translocation of YopH and YopE into host cells. This was also shown to impact the ability of Yersinia to block phagocytosis. One difficulty in studying YopN is to generate mutants that are not impaired in regulation of the T3SS. In this study we extended our previous work and were able to generate specific mutants within the central region of YopN. These mutants were predicted to be crucial for formation of a putative coiled-coil domain (CCD). Similar to the previously described deletion mutant of the central region, these mutants were all impaired in translocation of YopE and YopH. Interestingly, these YopN variants were not translocated into host cells. Importantly, when these mutants were introduced in cis on the virulence plasmid, they retained full regulatory function of T3SS expression and secretion. This allowed us to evaluate one of the mutants, yopNGAGA, in the systemic mouse infection model. Using in vivo imaging technology we could verify that the mutant was also attenuated in vivo and highly impaired to establish systemic infection.Entities:
Keywords: T3SS; Yersinia; YopN; mouse infection; virulence
Mesh:
Substances:
Year: 2019 PMID: 30488778 PMCID: PMC6298760 DOI: 10.1080/21505594.2018.1551709
Source DB: PubMed Journal: Virulence ISSN: 2150-5594 Impact factor: 5.882
Figure 1.Overview of predicted coiled-coil domain (CCD) and the different constructed mutants. Upper panel shows part of the YopN central region with putative CCM series. Middle panel shows the mutant substitutions constructed, YopNGAGA and YopNV83P, to disrupt the putative CCD. YopNRARA and YopNSASA are similar to YopNGAGA., with Arg (YopNRARA) and Ser (YopNSASA) instead of Gly substitutions. Lower panel shows CCD predictions of wt YopN and YopNGAGA.
Figure 2.Characterization of the different yopN mutants. Yersinia strains expressing the different yopN mutants were grown at 37°C for 3 h in either BHI +Ca+2 (non-inducing condition) or BHI – Ca+2 (inducing conditions). Whole culture samples (expression) or filtered supernatants precipitated with trichloroacetic acid (TCA) (secretion) were subjected to SDS-PAGE. Expression (a) and secretion (b) of the different YopN variants carrying an HA tag visualized by Western blotting using anti-HA antibody. Total expression of Yops visualized by Western blotting using total-Yop-antisera (c); and secretion of Yops visualized by Coomassie blue staining (d). Analysis of YopH translocation (E). YopH-Bla fusions were introduced instrains expressing the different yopN mutants. Translocation into infected HeLa cells was determined after 30 min by measuring green and blue fluorescence. Translocation levels were calculated as the ratio of blue:green signal after subtracting background signals. The results shown are from 4 independent experiments done as triplicates and normalized to pYopN-HA. The average values ± standard errors of the means (SEM) from 4 independent experiments are shown. All test samples were compared to pYopN using one-way ANOVA followed by the Bonferroni posttest; ****, P < 0.0001.
Figure 3.Translocation of the different yopN mutants. Translocation was determined using plasmids expressing C-terminal Bla fusions of the different Yop mutant proteins. These strains were used to infect HeLa cells for 30 min and YopN translocation levels were calculated as the ratio of blue:green fluorescence after subtracting background. The results shown are from 3 independent experiments performed in triplicates and normalized to infection with the strain expressing pYopN-Bla. The mean values ± SEM from 3 independent experiments are shown. All test samples were compared to the ΔyopB mutant strain expressing pYopN-Bla using one-way ANOVA followed by the Bonferroni posttest; ns, nonsignificant.
Figure 4.Yop expression and secretion in strains expressing YopN variants in cis. (a) The different strains were grown in 37°C for 3 h in either BHI +Ca+2 (non-inducing conditions) or BHI – Ca+2 (inducing conditions). Filtered supernatants were precipitated with TCA were subjected to SDS-PAGE and secreted proteins were visualized by Coomassie blue staining. (b) The different strains were grown in BHI+Ca+2 for 1 h at 37°C before depleting Ca+2 to induce the T3SS. After the induction for 30 min, whole cell samples were directly analysed for Yop expression and filtered supernatants were precipitated with TCA and then analysed for Yop secretion by western blotting using total Yop antisera. (c) Secreted YopH levels were quantified by PTPase assay. Strains were grown as in (b) and and PTPase activity in supernatants was analysed as described in materials and methods. 1 unit is equal to 1 mole of product produced per (min x ml supernatant x bacterial OD660). The results shown are from 3 independent experiments measured as triplicates. The average values ± SEM from 3 independent experiments are shown. The samples were analysed by Mann-Whitney test, ns, non-significant.
Figure 5.YopH and YopE translocation in strains expressing YopNGAGA in cis. YopH-Bla (a) or YopE-Bla (b) were introduced into wt, ΔyopB and yopN strains. HeLa cells were infected with the different strains for 30 min. Translocation levels were calculated as the ratio of blue:green signals after subtracting background levels. The results shown are from 3 independent experiments done as triplicates and normalised to cells infected with the wt strain. The mean values ± SEM from 3 independent experiments are shown. yopN samples were compared to wt using one-way ANOVA followed by the Bonferroni posttest; ***, P < 0.001.; ****, P < 0.0001.
Figure 6.Infection of BALB/c mice with bioluminescent Yersinia wt and yopN mutant. The infection was monitored using bioluminescent imaging for up to 16 days post infection (p.i.). (a) At each of days 3 and 5 p.i. one mouse infected with wt and one mouse infected with yopN were sacrificed. In all these mice, bacterial luminescence was measured from dissected liver (L), mesenteric lymph nodes (MLN), spleen (S) and intestines (I). (b) In addition to mice sacrificed in panel (a), at each of days 8 and 16 p.i. one mouse infected with yopN were sacrificed. The table shows luminescence levels from dissected livers, MLNs and spleens at 3 and 5 days p.i for wt and 3, 5, 8 and 16days p.i. for yopN
Strains and plasmids used in this study.
| Strain or plasmid | Relevant genotype | Reference |
|---|---|---|
| S17-1λ | RP4-2 Tc::Mu-Km::Tn7 (λ | [ |
| YPIII pIB102 | [ | |
| YPIII pIB604 | pIB102: | [ |
| YPIII pIB822 | pIB102: | [ |
| YPIII pIB823 | pIB102 expressing YopNRARA, Kmr | This study |
| YPIII pIB825 | pIB102 expressing YopNGAGA, Kmr | This study |
| YPIII pIB102 YopH-Bla | pIB102 expressing YopH6-99-Bla24-286, Kmr, Cmlr | [ |
| YPIII pIB604 YopH-Bla | pIB604 expressing YopH6-99-Bla24-286, Kmr, Cmlr | This study |
| YPIII pIB822 YopH-Bla | pIB822 expressing YopH6-99-Bla24-286, Kmr, Cmlr | [ |
| YPIII pIB825 YopH-Bla | pIB825 expressing YopH6-99-Bla24-286, Kmr, Cmlr | This study |
| YPIII pIB102 YopE-Bla | pIB102 expressing YopE6-86-Bla24-286, Kmr, Cmlr | [ |
| YPIII pIB604 YopE-Bla | pIB604 expressing YopE6-86-Bla24-286, Kmr, Cmlr | This study |
| YPIII pIB825 YopE-Bla | pIB825 expressing YopE6-86-Bla24-286, Kmr, Cmlr | This study |
| Xen4 pIB102 | pIB102: | Caliper Life Science |
| Xen4 pIB825 | Xen4 pIB102 expressing YopNGAGA, Kmr | This study |
| pSB1 | pBAD24 YopN-HA | [ |
| pRN62 | pBAD24 YopNΔ76-181-HA | [ |
| pRN65 | pBAD24 YopNRARA-HA | This study |
| pRN66 | pBAD24 YopNV83P-HA | This study |
| pRN67 | pBAD24 YopNSASA-HA | This study |
| pRN68 | pBAD24 YopNGAGA-HA | This study |
| pRN69 | pBAD24 YopNRARA-Bla24-286 | This study |
| pRN70 | pBAD24 YopNSASA-Bla24-286 | This study |
| pRN71 | pBAD24 YopNGAGA-Bla24-286 | This study |
| pRN72 | pBAD24 YopNV83P-Bla24-286 | This study |
| pRN73 | pDM4 containing | This study |
| pRN75 | pDM4 containing | This study |
| pSB22 | pBAD24 YopN-Bla24-286 | This study |
| pSB23 | pBAD24 YopNΔ76-181-Bla24-286 | This study |
| pNQ705-H-Bla | pNQ containing YopH6-99-β-lactamase fusion | [ |
| pNQ705-E-Bla | pNQ containing YopE6-86-β-lactamase fusion | [ |